Metastatic hepatocellular carcinoma with CD138 positivity: An unusual mimic of multiple myeloma?

Diagnostic Cytopathology

Volumn 36, Issue 10, 2008, Pages 742-748

  Ramalingam, Preetha ^a   Adeagbo, Bamidele ^a   Bollag, Ronie ^a   Lee, Jeffrey ^b   Reid Nicholson, Michelle ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

CD138; Fine needle aspiration; Hepatocellular carcinoma; Multiple myeloma

Indexed keywords

SYNDECAN 1;

AGED; ANAMNESIS; ARTICLE; ASPIRATION BIOPSY; BONE MARROW BIOPSY; CASE REPORT; CHROMOSOME ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; FLOW CYTOMETRY; HEPATITIS C; HUMAN; HUMERUS FRACTURE; IMMUNOHISTOCHEMISTRY; KIDNEY FAILURE; LIVER CELL CARCINOMA; LIVER METASTASIS; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; RADIODIAGNOSIS; TUMOR CELL;

AGED; BIOPSY, FINE-NEEDLE; CARCINOMA, HEPATOCELLULAR; DIAGNOSIS, DIFFERENTIAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MALE; MULTIPLE MYELOMA; SYNDECAN-1;

EID: 53049106446     PISSN: 87551039     EISSN: 10970339     Source Type: Journal    
DOI: 10.1002/dc.20888     Document Type: Article

References (27)

1. Sun WP, Wang FM, Xie F, et al. A novel anti-human syndecan-1 (CD138) monoclonal antibody 4B3: Characterization and application. Cell Mol Immunol 2007;4:209-214.
2. Al-Quran SZ, Yang L, Magill JM, Braylan RC, Douglas-Nikitin VK. Assessment of bone marrow plasma cell infiltrates in multiple myeloma: The added value of CD138 immunohistochemistry. Hum Pathol 2007;38:1779-1787.
3. Zellweger T, Ninck C, Mirlacher M, et al. Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer. Prostate 2003;55:20-29.
4. Day RM, Hao X, Ilyas M, Daszak P, Talbot IC, Forbes A. Changes in the expression of syndecan-1 in the colorectal adenoma-carcinoma sequence. Virchows Arch 1999;434:121-125.
5. Fujiya M, Watari J, Ashida T, et al. Reduced expression of syndecan-1 affects metastatic potential and clinical outcome in patients with colorectal cancer. Jpn J Cancer Res 2001;92:1074-1081.
6. Numa F, Hirabayashi K, Kawasaki K, et al. Syndecan-1 expression in cancer of the uterine cervix: Association with lymph node metastasis. Int J Oncol 2002;20:39-43.
7. Gokden N, Greene GF, Bayer-Garner IB, Spencer HJ, Sanderson RD, Gokden M. Expression of CD138 (Syndecan-1) in renal cell carcinoma is reduced with increasing nuclear grade. Appl Immunohistochem Mol Morphol 2006;14:173-177.
8. Inki P, Joensuu H, Grenman R, Klemi P, Jalkanen M. Association between syndecan-1 expression and clinical outcome in squamous cell carcinoma of the head and neck. Br J Cancer 1994;70:319-323.
9. Anttonen A, Kajanti M, Heikkila P, Jalkanen M, Joensuu H. Syndecan-1 expression has prognostic significance in head and neck carcinoma. Br J Cancer 1999;79:558-564.
10. Saqi A, Yun SS, Yu GH, et al. Utility of CD138 (syndecan-1) in distinguishing carcinomas from mesotheliomas. Diagn Cytopathol 2005;33:65-70.
11. Grogan TM, Van Camp B, Kyle RA, Muller-Hermelink HK, Harris NL. WHO histologic classification of mature B-cell neoplasms. In: Jaffe E, Harris N, Stein H, Vardiman J, editors. World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2001. p 120-187.
12. Chilosi M, Adami F, Lestani M, et al. CD138/syndecan-1: A useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies. Mod Pathol 1999;12:1101-1106.
13. Ishak KG, Goodman ZD, Stocker JT. Hepatocellular Carcinoma. In: Ishak KG, Goodman ZD, Stocker JT, editors. Atlas of tumor pathology. Tumors of the liver and intrahepatic bile ducts. Washington, DC: Armed Forces Institute of Pathology; 2001. p 199-230.
14. Nzeako UC, Goodman ZD, Ishak KG. Comparison of tumor pathology with duration of survival of North American patients with hepatocellular carcinoma. Cancer 1995;76:579-588.
15. Saad RS, Luckasevic TM, Noga CM, Johnson DR, Silverman JF, Liu YL. Diagnostic value of HepPar1, pCEA, CD10, and CD34 expression in separating hepatocellular carcinoma from metastatic carcinoma in fine-needle aspiration cytology. Diagn Cytopathol 2004;30:1-6.
16. Kambham N, Kong C, Longacre TA, Natkunam Y. Utility of syndecan-1 (CD138) expression in the diagnosis of undifferentiated malignant neoplasms: A tissue microarray study of 1,754 cases. Appl Immunohistochem Mol Morphol 2005;13:304-310.
17. Matsumoto A, Ono M, Fujimoto Y, Gallo RL, Bernfield M, Kohgo Y. Reduced expression of syndecan-1 in human hepatocellular carcinoma with high metastatic potential. Int J Cancer 1997;74:482-491.
18. Chen CL, Ou DL. Expression of syndecan-1 (CD138) in nasopharyngeal carcinoma is correlated with advanced stage and poor prognosis. Hum Pathol 2006;37:1279-1285.
19. Hirohashi S, Ishak KG, Kojiro M, et al. Hepatocellular carcinoma. In: Hamilton SR, Aaltonen LA, editors. World Health Organization classification of tumours, pathology and genetics of tumours of the digestive system. IARC Press: Lyon, France; 2000. p 159-172.
20. Han L, Bhan R, Zak I, et al. Metastatic hepatocellular carcinoma to the mandible masquerading as a parotid gland mass: A potential pitfall in the diagnosis by fine-needle aspiration biopsy. Diagn Cytopathol 2007;35:674-676.
21. Khalbuss WE, Bajestani S, D'Agostino HJ. Cytomorphology of a solitary left chest wall mass: An unusual presentation from unknown primary hepatocellular carcinoma. Diagn Cytopathol 2007;35:586-589.
22. Scolyer RA, Painter DM, Harper CG, Lee CS. Hepatocellular carcinoma metastasizing to the orbit diagnosed by fine-needle aspiration cytology. Pathology 1999;31:350-353.
23. Sarasquete ME, Garcia-Sanz R, Gonzalez D, et al. Minimal residual disease monitoring in multiple myeloma: A comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Haematologica 2005;90:1365-1372.
24. Ito Y, Yoshida H, Nakano K, et al. Syndecan-1 expression in thyroid carcinoma: Stromal expression followed by epithelial expression is significantly correlated with dedifferentiation. Histopathology 2003;43:157-164.
25. Bettencourt MC, Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Moul JW. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. J Urol 1996;156:1064-1068.
26. Bubendorf L, Tapia C, Gasser TC, et al. Ki67 labeling index in core needle biopsies independently predicts tumor-specific survival in prostate cancer. Hum Pathol 1998;29:949-954.
27. Wee A. Diagnostic utility of immunohistochemistry in hepatocellular carcinoma, its variants and their mimics. Appl Immunohistochem Mol Morphol 2006;14:266-272.